| Schedule of discontinued operations presented in consolidated statements of operations and consolidated balance sheets |
The following table presents the major classes of ADCL’s results within Net loss from discontinued operations, net of tax in the condensed consolidated statement of operations for the three and six months ended March 31, 2025: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | March 31, 2025 | | Fiscal Year Ended September 30, | | | Three Months | | Six Months | | | 2025 | | 2024 | Clinical laboratory service revenues | | $ | | 220,552 | | $ | 546,878 | | | $ | 572,928 | | $ | 1,317,930 | | | | | | | | | | | | | | | | Cost of clinical laboratory service revenues | | | | 245,223 | | | 493,681 | | | | 790,455 | | | 1,275,891 | | | | | | | | | | | | | | | | Gross profit | | | | (24,671) | | | 53,197 | | | | (217,527) | | | 42,039 | | | | | | | | | | | | | | | | Selling, general and administrative | | | | 59,292 | | | 123,401 | | | | 215,105 | | | 398,357 | Interest (income) | | | | (143) | | | 3,286 | | | | (3,301) | | | (55,819) | Other expense, net | | | | — | | | — | | | | 36,600 | | | — | Net loss from discontinued operations | | | | (84,106) | | | (66,918) | | | | (392,731) | | | (300,499) | Provision for income taxes | | | | — | | | — | | | | — | | | — | Net loss from discontinued operations, net of tax | | $ | | (84,106) | | $ | (66,918) | | | $ | (392,731) | | $ | (300,499) |
Assets and liabilities of discontinued operations associated with ADCL presented in the consolidated balance sheets as of March 31, 2026 and September 30, 2025 are included in the following table: | | | | | | | | | | | | | | | | March 31, | | September 30, | | | 2026 | | 2025 | ASSETS | | | | | | | Cash and cash equivalents | | $ | — | | $ | 6,971 | Accounts receivable, net | | | — | | | — | Inventories | | | — | | | — | Prepaid expenses and other current assets | | | — | | | — | Total current assets of discontinued operations | | | — | | | 6,971 | Property and equipment, net | | | — | | | — | Total assets of discontinued operations | | | — | | | 6,971 | | | | | | | | LIABILITIES | | | | | | | Accounts payable and accrued liabilities | | | — | | | — | Total liabilities of discontinued operations | | $ | — | | $ | — |
|
| | | | | | | | | | | | | | | | | | Fiscal Year Ended September 30, | | | | 2025 | | 2024 | | Clinical laboratory service revenues | | $ | 572,928 | | $ | 1,317,930 | | | | | | | | | | Cost of clinical laboratory service revenues | | | 790,455 | | $ | 1,275,891 | | | | | | | | | | Gross profit | | | (217,527) | | | 42,039 | | | | | | | | | | Selling, general and administrative | | | 215,105 | | | 398,357 | | Interest (income) | | | (3,301) | | | (55,819) | | Other expense, net | | | 36,600 | | | — | | Net loss from discontinued operations | | | (392,731) | | | (300,499) | | Provision for income taxes | | | — | | | — | | Net loss from discontinued operations, net of tax | | $ | (392,731) | | $ | (300,499) | |
| | | | | | | | | | | | | | | | September 30, | | September 30, | | | 2025 | | 2024 | ASSETS | | | | | | | Cash and cash equivalents | | $ | 6,971 | | $ | 578,732 | Accounts receivable, net | | | — | | | 33,760 | Inventories | | | — | | | 5,867 | Prepaid expenses and other current assets | | | — | | | 59,787 | Total current assets of discontinued operations | | | 6,971 | | | 678,146 | Property and equipment, net | | | — | | | 94,337 | Total assets of discontinued operations | | | 6,971 | | | 772,483 | | | | | | | | LIABILITIES | | | | | | | Accounts payable and accrued liabilities | | | — | | | 56,061 | Total liabilities of discontinued operations | | $ | — | | $ | 56,061 |
|